Background: Drug-drug interactions (DDIs) are a critical challenge in managing cancer patients receiving polytherapy, often due to comorbid conditions. DDIs can arise through pharmacokinetic mechanisms, affecting drug absorption, distribution, metabolism, or excretion, or through pharmacodynamic interactions, altering drug target binding or leading to overlapping toxicities. These interactions can compromise treatment efficacy, exacerbate adverse events, and increase patient morbidity and mortality. Methods: Effective DDI management requires a multidisciplinary approach that integrates oncologists and pharmacologists. Key factors influencing DDIs include the pharmacological properties of drugs, patient-specific clinical and genetic characteristics, and the timing of therapy exposure. Identifying and mitigating DDIs also relies on patients' adherence to treatment and their early reporting of adverse events. Results: This article proposes a structured framework for DDI assessment in oncology, emphasizing actionable strategies tailored to the complexities of cancer care. The framework incorporates the evaluation of pharmacokinetic and pharmacodynamic interactions, identification of high-risk drug combinations, and the use of therapeutic drug monitoring (TDM) and pharmacogenetics to individualize treatment. Specific recommendations for managing QTc-prolonging interactions, CYP3A4-mediated metabolism, and P-glycoprotein (P-gp)-related transport issues are highlighted. Conclusions: By fostering collaboration among health care professionals and leveraging advanced tools, the proposed approach aims to optimize therapeutic outcomes while minimizing DDI risks. The manuscript underscores the importance of tailored strategies in oncology, advocating for the integration of pharmacological insights into clinical practice to enhance patient safety and treatment efficacy.
Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)
Del Re, M;
2025-01-01
Abstract
Background: Drug-drug interactions (DDIs) are a critical challenge in managing cancer patients receiving polytherapy, often due to comorbid conditions. DDIs can arise through pharmacokinetic mechanisms, affecting drug absorption, distribution, metabolism, or excretion, or through pharmacodynamic interactions, altering drug target binding or leading to overlapping toxicities. These interactions can compromise treatment efficacy, exacerbate adverse events, and increase patient morbidity and mortality. Methods: Effective DDI management requires a multidisciplinary approach that integrates oncologists and pharmacologists. Key factors influencing DDIs include the pharmacological properties of drugs, patient-specific clinical and genetic characteristics, and the timing of therapy exposure. Identifying and mitigating DDIs also relies on patients' adherence to treatment and their early reporting of adverse events. Results: This article proposes a structured framework for DDI assessment in oncology, emphasizing actionable strategies tailored to the complexities of cancer care. The framework incorporates the evaluation of pharmacokinetic and pharmacodynamic interactions, identification of high-risk drug combinations, and the use of therapeutic drug monitoring (TDM) and pharmacogenetics to individualize treatment. Specific recommendations for managing QTc-prolonging interactions, CYP3A4-mediated metabolism, and P-glycoprotein (P-gp)-related transport issues are highlighted. Conclusions: By fostering collaboration among health care professionals and leveraging advanced tools, the proposed approach aims to optimize therapeutic outcomes while minimizing DDI risks. The manuscript underscores the importance of tailored strategies in oncology, advocating for the integration of pharmacological insights into clinical practice to enhance patient safety and treatment efficacy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
